基本信息
views: 3
Career Trajectory
Bio
Professor Hughes had a significant leadership role in the establishment of the molecular response criteria and kinase domain mutation screening guidelines that are used world-wide to monitor response and resistance in chronic myeloid leukaemia (CML). He has been a principal investigator on many of the key Global and Australian CML trials that have shaped the way tyrosine-kinase inhibitors (TKI's) are selected and sequenced. He has been a leader in the area of treatment-free remission (TFR) and influential in the recent recommendations to make TFR a mainstream goal of therapy. He has published over 300 papers with over 54,000 citations.
In recognition of his outstanding contributions to the field, Professor Hughes was awarded an L3 Investigator Grant from the NHMRC (2022-2026) for his project "A curative approach for chronic myeloid leukaemia".
In recognition of his outstanding contributions to the field, Professor Hughes was awarded an L3 Investigator Grant from the NHMRC (2022-2026) for his project "A curative approach for chronic myeloid leukaemia".
Research Interests
Papers共 711 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Leukemiapp.1-4, (2024)
Blood Neoplasiapp.100014, (2024)
Leukemiano. 5 (2024): 947-950
LEUKEMIA (2024)
Leukemia (2024)
Lynette Chee, Nora Lee, Andrew Grigg, Melissa Chen, Anthony Schwarer, Jeff Szer, Sumita Ratnasingam, Sonia Raj, Pohan Lukito, David Yeung,Timothy Hughes, Naranie Shanmuganathan
Internal medicine journal (2024)
Leukemiapp.1-12, (2024)
Blood (2024)
Leukemiapp.1-4, (2024)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn